• 1
    Bossi L. Fetal effects of anticonvulsants. In: MorselliPL, Pip-pengerCE, PenryJK, eds. Antiepileptic Drug Therapy in Pediatrics. New York : Raven Press, 1983:3764.
  • 2
    Hanson JW, Myrainthopoulos NC, Sedgewick Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Pediatrics 1976;89:6628.
  • 3
    Hiilesmaa VK, Teramo K, Granström M-L, Bardy AH. Fetal head growth retardation associated with maternal antiepileptic drugs. Lancet 1981;July 25:1657.
  • 4
    Battino D, Granata T, Binelli S, et al. Intrauterine growth in the offspring of epileptic mothers. Acta Neurol Scand 1992;86:5557.
  • 5
    Steegers-Theunissen R, Renier W, Borm G, et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Res 1994;18:2619.
  • 6
    Bertollini R, Källén B, Mastroiacovo P, Robert E. Anticonvulsant drugs in monotherapy: effects on the fetus. Eur J Epidemiol 1987;3:16471.
  • 7
    Mastroiacovo P, Bertollini R, Licata D, et al. Fetal growth in the offspring of epileptic women: results of an Italian multicentric cohort study. Acta Neurol Scand 1988;78:1104.
  • 8
    Källén B. A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurol Scand 1986; 73:2539.
  • 9
    Källén B. Maternal carbamazepine and infant spina bifida. Reprod Toxicol 1994;8:2035.
  • 10
    Wide K, Winbladh B, Tomson T, Sars-Zimmer K, Berggren E. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population based case-control study. Dev Med Child Neurol 2000;42:8792.
  • 11
    Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994;35:12230.
  • 12
    Gaily E, Kantola-Sorsa E, Granström M-L. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990;32:40314.
  • 13
    Dansky LV, Finnell LV. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiological and experimental findings spanning three decades. 2 Human studies. Reprod Toxicol 1991;5:30135.
  • 14
    Cnattinigius S, Ericsson A, Gunnarskog J, Källén B. A quality study of medical birth registry. Scand J Soc Med 1990;18:1438.
  • 15
    Källén B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998;105:87781.
  • 16
    Källén B. A birth weight for gestational age standard based on data in the Swedish Medical Birth Registry, 1985–1989. Eur J Epidemiol 1995;11:6016.
  • 17
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:71948.
  • 18
    Miettinen OS. Simple interval estimation of risk ratio. Am J Epidemiol 1974;100:5156.
  • 19
    Armitage P. Test for linear trend in proportions and frequencies. Biometrica 1955;11:37586.
  • 20
    Battino D, Kaneko S, Andermann E, et al. Intrauterine growth in the offspring of epileptic women: a prospective multicenter study. Epilepsy Res 1999;36:5360.
  • 21
    Robert E, Källén B. In utero exposure to carbamazepine: effects on the fetus. Issues Rev Teratol 1994;7:3755.
  • 22
    Hiilesmaa VK, Teramo K, Granström M-L. Fetal head growth retardation associated with maternal antiepileptic drugs. Lancet 1981;July 25(8239):1657.
  • 23
    Gaily E, Granström M-L, Hiilesmaa V, Bardy A. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res 1990;3:21722.